BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 33784904)

  • 1. A Novel 85-Gene Expression Signature Predicts Unfavorable Prognosis in Acute Myeloid Leukemia.
    Lai Y; Sheng L; Wang J; Zhou M; OuYang G
    Technol Cancer Res Treat; 2021; 20():15330338211004933. PubMed ID: 33784904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
    Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
    Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying a novel 5-gene signature predicting clinical outcomes in acute myeloid leukemia.
    Sha K; Lu Y; Zhang P; Pei R; Shi X; Fan Z; Chen L
    Clin Transl Oncol; 2021 Mar; 23(3):648-656. PubMed ID: 32776271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
    Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
    J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
    Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
    Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival prediction in acute myeloid leukemia using gene expression profiling.
    Lai B; Lai Y; Zhang Y; Zhou M; OuYang G
    BMC Med Inform Decis Mak; 2022 Mar; 22(1):57. PubMed ID: 35241089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia.
    Guo C; Gao YY; Ju QQ; Zhang CX; Gong M; Li ZL
    BMC Cancer; 2020 Sep; 20(1):841. PubMed ID: 32883226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
    Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
    Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics Analysis to Determine Prognostic Mutations of 72 de novo Acute Myeloid Leukemia Cases from the Cancer Genome Atlas (TCGA) with 23 Most Common Mutations and no Abnormal Cytogenetics.
    Welsh KJ; Nedelcu E; Wahed A; Bai Y; Dasgupta A; Nguyen A
    Ann Clin Lab Sci; 2015; 45(5):515-21. PubMed ID: 26586702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of tumor protein p53 mutation-based prognostic signatures for acute myeloid leukemia.
    Xie J; Chen K; Han H; Dong Q; Wang W
    Curr Res Transl Med; 2022 Sep; 70(4):103347. PubMed ID: 35483237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia.
    Fu Y; Zhu H; Wu W; Xu J; Chen T; Xu B; Qian S; Li J; Liu P
    Leuk Lymphoma; 2014 Feb; 55(2):371-7. PubMed ID: 23713453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and Clinicopathologic Features of RUNX1 Mutations in Patients With Acute Myeloid Leukemia Not Otherwise Specified.
    You E; Cho YU; Jang S; Seo EJ; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park YM; Lee JK; Park CJ
    Am J Clin Pathol; 2017 Jul; 148(1):64-72. PubMed ID: 28927163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
    Zhao Y; Zhang T; Zhao Y; Zhou J
    Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octamer-binding transcription factor 4 correlates with complex karyotype, FLT3-ITD mutation and poorer risk stratification, and predicts unfavourable prognosis in patients with acute myeloid leukaemia.
    Xiang Y; Zhou X
    Hematology; 2018 Dec; 23(10):721-728. PubMed ID: 29950146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.